| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $14.2M | -8.0% |
| SG&A Expense | $16.0M | -35.5% |
| Operating Income | -$82.0M | -103.6% |
| Income Tax | $0 | — |
| Net Income | -$73.9M | -110.4% |
| EPS (Basic) | -$1.53 | -17.7% |
| EPS (Diluted) | -$1.53 | -17.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $87.2M | -6.3% |
| Short-term Investments | $63.7M | +365.4% |
| Current Assets | $154.9M | +40.5% |
| Total Assets | $217.2M | +96.6% |
| Current Liabilities | $4.9M | +74.1% |
| Total Liabilities | $5.3M | +84.9% |
| Stockholders' Equity | $211.9M | +96.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.6M | +24.5% |
| Investing Cash Flow | -$121.1M | -275.5% |
| Financing Cash Flow | $130.7M | — |